James Alecxih to Lead TriSalus’ Device Technology Business

TriSalus Life Sciences Inc. has recruited James “Jim” Alecxih to fulfill the newly created role of president, Device Technology Business.
 
Alecxih brings to TriSalus more than 30 years of experience in product development, launch and marketing strategies. His responsibilities will include overseeing the growth and development of TriSalus’ TriNav Infusion System, including device engineering, device quality, sales, marketing, and market access. Used in more than 17,000 procedures, TriNav is a U.S. Food and Drug Administration-cleared therapy delivery technology that leverages the Pressure-Enabled Drug Delivery (PEDD) method to improve therapy uptake and tumor response.
 
“Jim’s experience in successfully manufacturing, commercializing and bringing to market novel medical devices is ideally suited to the work we are doing at TriSalus to improve treatments for patients with liver and pancreatic cancers,” TriSalus President and CEO Mary Szela said. “Our TriNav Infusion System is in its growth stage, and we are confident that Jim will help us capture the opportunities ahead to take the company to the next level. We welcome Jim to TriSalus and I look forward to working together to improve the lives of patients through our disruptive technology.”

Before joining TriSalus, Alecxih was president and CEO of ViveBio Scientific, a medical device company focused on blood transport and storage systems. Previously, he worked as chief commercial officer for ViewRay, an early-stage radiation oncology company, where he managed global sales, marketing, and training. He also spent 15 years at Intuitive Surgical Inc., maker of the da Vinci surgical and Ion endoluminal systems, where he led an 850-person sales organization across the United States and Canada and exceeded revenue targets for 51 consecutive quarters.
 
“I am excited to join TriSalus during this pivotal period for the company. Over the course of my career, I’ve worked with a number of innovative medtech companies, and I was drawn to TriSalus because of the company’s unique platform and the ways in which its TriNav system can improve therapeutic delivery and tumor targeting,” Alecxih said. “I look forward to collaborating with Mary Szela, Dr. Katz and the rest of the team to enable better cancer treatment for patients and drive enhanced outcomes across multiple indications.”
 
TriSalus is an oncology company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors. Its proprietary platform approach addresses immune dysfunction in liver and pancreatic tumors by combining its drug delivery technology with immunotherapeutics. The TriSalus platform comprises the TriNav Infusion System and SD-101, a class C toll-like receptor 9 (TLR9) agonist. TriNav is a U.S. Food and Drug Administration-cleared device that is designed to administer established and emerging therapeutics. TriNav is the latest TriSalus asset for the proprietary PEDD method of administration which has been shown to overcome intratumoral pressure through modulation of pressure and flow to increase delivery of therapeutic agents.
 
Last fall, TriSalus entered into a definitive merger agreement with MedTech, a publicly traded special purpose acquisition company. Upon the deal’s closing, expected sometime this quarter, the combined company will be a publicly traded entity and its common stock will be listed on the NASDAQ Stock Exchange under the ticker “TLSI.” 

MedTech is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. MedTech has stated a focus on the medical technology industry in the United States and other developed countries.